Clinical Trial Update: Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated hypofractionated IMRT with temozolomide and bevacizumab for glioblastoma multiforme; study status completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Bevacizumab (bevacizumab)
• Temozolomide (Temozolomide)
• hypofractionated intensity-modulated radiation therapy

Snippet

Sponsor: University of Colorado, Denver | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2019-04-12